Related Experiment Video
Updated: Apr 19, 2026
Assessing Microglial Phagocytosis of Myelin Debris in vitro Under Repeated Magnetic Stimulation
Published on: June 17, 2025
n-3 PUFA supplementation benefits microglial responses to myelin pathology
Songela Chen1, Haiyue Zhang2, Hongjian Pu3
1Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA.
Abstract:
Microglia represent rational but challenging targets for improving white matter integrity because of their dualistic protective and toxic roles. The present study examines the effect of Omega-3 polyunsaturated fatty acids (n-3 PUFAs) on microglial responses to myelin pathology in primary cultures and in the cuprizone mouse model of multiple sclerosis (MS), a devastating demyelination disease. Docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), the two main forms of n-3 PUFAs in the brain, inhibited the release of nitric oxide and tumor necrosis factor-α from primary microglia upon IFN-γ and myelin stimulation. DHA and EPA also enhanced myelin phagocytosis in vitro. Therefore, n-3 PUFAs can inhibit inflammation while at the same time enhancing beneficial immune responses such as microglial phagocytosis. In vivo studies demonstrated that n-3 PUFA supplementation reduced cuprizone-induced demyelination and improved motor and cognitive function. The positive effects of n-3 PUFAs were accompanied by a shift in microglial polarization toward the beneficial M2 phenotype both in vitro and in vivo. These results suggest that n-3 PUFAs may be clinically useful as immunomodulatory agents for demyelinating diseases through a novel mechanism involving microglial phenotype switching.
Insights
Omega-3 polyunsaturated fatty acids (n-3 PUFAs) reduce inflammation and enhance myelin clearance by microglia. Supplementation improved function in a multiple sclerosis model, suggesting therapeutic potential for demyelinating diseases.
Area of Science:
- Neuroimmunology
- Cellular and Molecular Neuroscience
Background:
- Microglia play a dual role in white matter integrity, exhibiting both protective and toxic functions.
- Targeting microglia is a promising strategy for treating demyelinating diseases like multiple sclerosis (MS).
Purpose of the Study:
- To investigate the effects of Omega-3 polyunsaturated fatty acids (n-3 PUFAs) on microglial responses to myelin pathology.
- To evaluate the therapeutic potential of n-3 PUFAs in a mouse model of MS.
Main Methods:
- Primary microglial cultures and the cuprizone mouse model of demyelination were used.
- Assays included measuring inflammatory mediators (nitric oxide, TNF-α), myelin phagocytosis, and motor/cognitive function.
- Microglial polarization was assessed in vitro and in vivo.
Main Results:
- n-3 PUFAs (DHA and EPA) inhibited pro-inflammatory mediators and enhanced myelin phagocytosis by microglia.
- In vivo, n-3 PUFA supplementation reduced demyelination and improved motor and cognitive deficits in the cuprizone model.
- A shift towards the beneficial M2 microglial phenotype was observed with n-3 PUFA treatment.
Conclusions:
- n-3 PUFAs exhibit immunomodulatory effects on microglia, reducing inflammation while promoting beneficial functions.
- Microglial phenotype switching is a key mechanism underlying the therapeutic effects of n-3 PUFAs in demyelinating diseases.
- n-3 PUFAs hold promise as a novel therapeutic strategy for managing MS and other demyelinating conditions.
